In this late-breaking science interview, we are joined by Prof Frederick Zimmermann (Catharina Hospital, NL) to discuss the findings from a 3-year follow-up of the FAME III trial.
The objective of the FAME 3 trial was to demonstrate the noninferiority of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) in patients with three-vessel disease. Eligible patients were randomly assigned to either FFR-guided PCI (757) or CABG (743) in a 1:1 ratio. The results at 3 years demonstrate no significant difference in death, MI and stroke at 3 years.
Interview Questions
-What is the importance of the FAME 3 trial?
-Could you provide a brief overview of the methodology used and the patient population involved in the FAME 3 trial?
-What are the key findings at three years?
-What are some of the limitations of this trial?
-In the context of three-vessel disease, which patients would potentially benefit from FFR-guided PCI?
-What are the next steps and what are the remaining knowledge gaps?
Recorded on-site at EuroPCR 2023, Paris.
Visit Radcliffe Cardiology: [ Ссылка ]
Visit Radcliffe Vascular: [ Ссылка ]
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: [ Ссылка ]
Follow us on X: [ Ссылка ]
